Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.074
Neutral
RSI(14)
50.198
Neutral
STOCH(KDJ)(9,3,3)
17.388
Sell
ATR(14)
0.414
Low Volatility
CCI(14)
-11.176
Neutral
Williams %R
92.053
Oversold
TRIX(12,20)
0.350
Sell
StochRSI(14)
4.953
Sell
Search
CorMedix Inc
CRMDAdd to Watchlist
7.550USD
-0.380-4.79%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
591.88MMarket Cap
3.10P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of CorMedix Inc
Currency: USD Updated: 2026-05-15Key Insights
CorMedix Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 51 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CorMedix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
CorMedix Inc Highlights
StrengthsRisks
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 3.34, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 43.28M shares, decreasing 30.09% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 7.40K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
15.000
Target Price
+100.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of CorMedix Inc is 9.20, ranking 11 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 128.62M, representing a year-over-year increase of 312.10%, while its net profit experienced a year-over-year increase of 4.13%.
Score
Financials
8.17
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.81
CorMedix Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of CorMedix Inc is 6.70, ranking 114 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 3.34, which is 1784.79% below the recent high of 62.87 and 1359.07% above the recent low of -41.99.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 51/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of CorMedix Inc is 8.29, ranking 46 out of 155 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 22.00 and a low of 14.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
14.857
Target Price
+87.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
CorMedix Inc
CRMD
7
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of CorMedix Inc is 6.89, ranking 70 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 8.57 and the support level at 6.90, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
7.630
Sell
MA10
7.767
Sell
MA20
7.656
Sell
MA50
7.142
Buy
MA100
7.765
Sell
MA200
9.662
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CorMedix Inc is 5.19, ranking 73 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.43
VaR
+5.76%
240-Day Maximum Drawdown
+62.26%
240-Day Volatility
+73.56%
Return
Best Daily Return
60 days
+5.73%
120 days
+6.74%
5 years
+30.16%
Worst Daily Return
60 days
-11.52%
120 days
-32.77%
5 years
-57.45%
Sharpe Ratio
60 days
+0.71
120 days
-0.49
5 years
+0.49
Risk Assessment
Maximum Drawdown
240 days
+62.26%
3 years
+62.26%
5 years
+62.63%
Return-to-Drawdown Ratio
240 days
-0.65
3 years
+0.50
5 years
+0.10
Skewness
240 days
-1.07
3 years
+0.29
5 years
-1.04
Volatility
Realised Volatility
240 days
+73.56%
5 years
+88.67%
Standardised True Range
240 days
+7.52%
5 years
+5.19%
Downside Risk-Adjusted Return
120 days
-46.15%
240 days
-46.15%
Maximum Daily Upside Volatility
60 days
+48.27%
Maximum Daily Downside Volatility
60 days
+38.97%
Liquidity
Average Turnover Rate
60 days
+1.79%
120 days
+2.92%
5 years
--
Turnover Deviation
20 days
-38.28%
60 days
-34.09%
120 days
+7.24%
Peer Comparison
Pharmaceuticals
CorMedix Inc
CRMD
7.36 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
